Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

Most Patients with Advanced Melanoma Who Received Pre-Surgical Immunotherapy Remain Alive and Disease Free Four Years Later

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage III melanoma remained alive, according to new results from a study led by researchers at The University of Texas MD Anderson Cancer Center.

July 10, 2025


July 10 2025

July 9 2025

July 8 2025

July 7 2025

July 6 2025

July 5 2025

July 4 2025

July 3 2025

July 2 2025

July 1 2025

June 30 2025

June 29 2025

June 28 2025

June 27 2025